Why Arcturus Therapeutics Stock Is Plunging Today - Motley Fool

Why Arcturus Therapeutics Stock Is Plunging Today  Motley FoolArcturus Therapeutics shares slide 55% after COVID vaccine data are deemed 'underwhelming'  MarketWatchArcturus Therapeutics Received Approval from Singapore Health Sciences Authority to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate and Provides New and Updated Clinical and Preclinical Data  Yahoo FinanceSingapore, Arcturus see 'good response' in first trial phase of Lunar-Cov19 v